Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Bonnetain

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trialsVincenzo Valentini, Ruud G P M van Stiphout, Guido Lammering, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 27, 2015
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancerVincenzo Valentini, Ruud G P M van Stiphout, Guido Lammering, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Oncotarget|October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysisMarion Savina, Saskia Litière, Antoine Italiano, et al.
International Journal of Oncology|February 6, 2019
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II studyBenoist Chibaudel, Jean-Baptiste Bachet, Thierry André, et al.
The Lancet. Oncology|October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trialChristophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Cancer Medicine|June 3, 2016
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastomaBrice Paquette, Dewi Vernerey, Bruno Chauffert, et al.
Cancer|December 13, 2017
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromesFabio Efficace, Francesco Cottone, Gregory Abel, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2011
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trialsVincenzo Valentini, Ruud G P M van Stiphout, Guido Lammering, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 27, 2015
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancerVincenzo Valentini, Ruud G P M van Stiphout, Guido Lammering, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Oncotarget|October 24, 2018
Surrogate endpoints in advanced sarcoma trials: a meta-analysisMarion Savina, Saskia Litière, Antoine Italiano, et al.
International Journal of Oncology|February 6, 2019
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II studyBenoist Chibaudel, Jean-Baptiste Bachet, Thierry André, et al.
The Lancet. Oncology|October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trialChristophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
Bulletin Du Cancer|April 4, 2012
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]Isabelle Ray-Coquard, Franck Chauvin, Eric Leblanc, et al.
Cancer Medicine|June 3, 2016
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastomaBrice Paquette, Dewi Vernerey, Bruno Chauffert, et al.
Cancer|December 13, 2017
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromesFabio Efficace, Francesco Cottone, Gregory Abel, et al.
Pageof 17